Sung Won Song
Director/Board Member bei JW (CAYMAN) THERAPEUTICS CO. LTD
Profil
Sung Won Song is currently a Director at EpimAb Biotherapeutics, Inc. and a Non-Executive Director at JW (Cayman) Therapeutics Co. Ltd.
Dr. Song has a graduate degree from The Trustees of Columbia University in The City of New York, a doctorate degree from The Ohio State University, and an undergraduate degree from Korea University.
Aktive Positionen von Sung Won Song
| Unternehmen | Position | Beginn |
|---|---|---|
| JW (CAYMAN) THERAPEUTICS CO. LTD | Director/Board Member | 29.08.2023 |
EpimAb Biotherapeutics, Inc.
 EpimAb Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology EpimAb Biotherapeutics, Inc. is a Chinese clinical stage biopharmaceutical company that specializes in developing multispecific antibodies. The company is based in Shanghai, China. The company utilizes its in-house research and technology capabilities, including the proprietary fit-ig® and mat-fab bispecific platforms, to generate and advance a unique pipeline of transformative preclinical and clinical assets that aim to benefit cancer patients. The company was founded in 2016 by Chen Bing Wu, who has been the CEO since 2016. | Director/Board Member | - |
Ausbildung von Sung Won Song
| The Trustees of Columbia University in The City of New York | Graduate Degree |
| The Ohio State University | Doctorate Degree |
| Korea University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| JW (CAYMAN) THERAPEUTICS CO. LTD | Health Technology |
| Private Unternehmen | 1 |
|---|---|
EpimAb Biotherapeutics, Inc.
EpimAb Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology EpimAb Biotherapeutics, Inc. is a Chinese clinical stage biopharmaceutical company that specializes in developing multispecific antibodies. The company is based in Shanghai, China. The company utilizes its in-house research and technology capabilities, including the proprietary fit-ig® and mat-fab bispecific platforms, to generate and advance a unique pipeline of transformative preclinical and clinical assets that aim to benefit cancer patients. The company was founded in 2016 by Chen Bing Wu, who has been the CEO since 2016. | Health Technology |
